Author Affiliations: National Cancer Institute, CCR, National Institutes of Health, Bethesda, Md (Drs Liotta and Kohn); and Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Md (Dr Petricoin).
Contempo Updates Section Editor: Janet M.
Torpy, MD, Fishbein Fellow.
The cause of most human disease lies in the functional dysregulation
of protein interactions. Proteomics, which includes the study of cellular
protein interactions, has evolved from advances in scientific knowledge and
technology. Understanding the role that protein networks play in disease will
create enormous clinical opportunities, because these pathways represent the
drug targets of the next decade. In the future, entire cellular networks,
not just one dysregulated protein, will be the target of therapeutics. The
next technologic leap will be the application of proteomic technologies to
the bedside. Soon it will be possible to analyze the state of protein signal
pathways in the disease-altered cells before, during, and after therapy, heralding
the advent of true patient-tailored therapy.
Liotta LA, Kohn EC, Petricoin EF. Clinical ProteomicsPersonalized Molecular Medicine. JAMA. 2001;286(18):2211-2214. doi:10.1001/jama.286.18.2211